HomeLSTA • NASDAQ
add
Lisata Therapeutics Inc
Previous close
$2.77
Day range
$2.65 - $2.82
Year range
$1.87 - $4.20
Market cap
23.69M USD
Avg Volume
51.24K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | 70.00K | — |
Operating expense | 4.94M | -10.59% |
Net income | -4.66M | 7.63% |
Net profit margin | -6.66K | — |
Earnings per share | -0.54 | 11.48% |
EBITDA | -4.82M | 11.94% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 21.97M | -42.58% |
Total assets | 25.16M | -40.90% |
Total liabilities | 4.38M | -4.17% |
Total equity | 20.78M | — |
Shares outstanding | 8.76M | — |
Price to book | 1.14 | — |
Return on assets | -44.96% | — |
Return on capital | -52.95% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | -4.66M | 7.63% |
Cash from operations | -3.96M | 25.12% |
Cash from investing | 505.00K | -95.69% |
Cash from financing | 64.00K | 100.00% |
Net change in cash | -3.38M | -152.13% |
Free cash flow | -2.53M | 28.81% |
About
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Founded
1980
Headquarters
Website
Employees
26
